Welcome to MississippiLifeScience.com

This network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About Mississippi's BioHistory

Through Mississippi BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of Mississippi.

Local News...

Free News Release Posting & Archiving Service


• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• Enhanced pain management for blood draw and IV insertions in children has many benefits  According to a new survey of nurses, increasing the use of non-pharmacologic interventions (such as distraction techniques, parental coaching, and comfort positions) and pharmacologic options that do not cause treatment delays or vasoconstriction would enhance patient and staff satisfaction.
  Anesiva, Inc.  May 08, 2008  
  
  
• FDA approves Strattera(R) for maintenance of ADHD in children and adolescents  Eli Lilly and Company announced that the United States Food and Drug Administration has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents.
  Eli Lilly and Company  May 08, 2008  
  
  
• BioCryst reports first quarter 2008 financial results and clinical update  BioCryst Pharmaceuticals announced financial results for the quarter ended March 31, 2008. The Company reported revenues of $10.8M in the first quarter of 2008, compared to $9.2M in the first quarter of 2007.
  BioCryst Pharmaceuticals, Inc.  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/13/2008: 2008 Healthcare Investor & Corporate Development Conference
• 05/13/2008: Recruiting 2008 Conference & Expo

More... | Submit Event | Event Advertising...